Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Abstract

In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

“…24 A collaborative study is underway to determine if the adult HL expression signature can accurately predict outcomes in pediatric HL, or if a different gene expression set is needed. 25 In the future, a more complete understanding of the molecular pathogenesis of pediatric HL will provide clues to new and better treatments directed toward tumor-specific molecular lesions. Flowsorting tissue for H/RS and intratumor T cells and optimizing lowinput exome sequencing is beginning to overcome the limitations of genomic evaluation in HL.…”

Imaging of the Pediatric Thymus and Thymic Disorders

“…HL is typically seen in older children and adolescents and is staged using the Ann Arbor staging classification that is based on the number of sites of lymph node involvement, presence of extranodal disease, and history of B symptoms, such as fever, night sweats, or weight loss (Table 1). The presence of multinucleated Reed Sternberg cells define HL histologically, but multiple histological subtypes exist with nodular sclerosis being the most common in adolescents and mixed cellularity subtype being most common in children (Kelly et al 2013). While HL only represents 40-50 % of all cases of pediatric lymphoma, thoracic manifestation of disease is seen in up to 85 % of patients at the time of diagnosis (Bae and Lee 2010).…”

“…Approximately 1,100 children under 20 years of age are diagnosed with Hodgkin lymphoma (HL) each year in the US with the 5-year survival rate exceeding 90 % (Kelly et al 2013). HL is typically seen in older children and adolescents and is staged using the Ann Arbor staging classification that is based on the number of sites of lymph node involvement, presence of extranodal disease, and history of B symptoms, such as fever, night sweats, or weight loss (Table 1).…”

Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

“…Lymphomas are among the most common malignancies of childhood and include Hodgkin Lymphoma and a variety of non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, Burkitt lymphoma, and anaplastic large cell lymphoma [83,84]. Hodgkin lymphoma, derived from the B-cell lineage, is characterized by Reed-Sternberg cells, is the most common malignancy of adolescence, and currently has a five-year survival greater than 90 % with current chemo-and radiotherapy protocols.…”